Alembic Pharmaceuticals Acquires Utility Therapeutics for Strategic US Expansion

Alembic Pharmaceuticals has acquired Utility Therapeutics Ltd for USD 12 million to enhance its presence in the US market. This acquisition allows Alembic to commercialize the FDA-approved Pivya, targeting urinary tract infections. Alembic aims to expand its footprint in the branded pharmaceutical sector.

Alembic Pharmaceuticals has announced the acquisition of Utility Therapeutics Ltd in a transaction valued at USD 12 million, a strategic move aimed at bolstering its footprint in the American pharmaceuticals market.

The deal, executed by its US subsidiary, Alembic Pharmaceuticals, Inc, enables Alembic to move into branded prescription products, starting with the commercialization of Pivya, a recently FDA-approved treatment for uncomplicated urinary tract infections.

Alembic's Managing Director, Pranav Amin, emphasized the strategic entry into the specialty and branded prescription arena, signaling a significant shift from their generic pharmaceutical roots. With plans to launch Pivya in Q4 2025, Alembic aims to cater to female patients across the US.

(With inputs from agencies.)